As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...
It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people ...
Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...
Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...
Hosted on MSN11mon
Fake Ozempic - FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High DemandFDA and Novo Nordisk are testing the seized products and do not yet have information about the drugs' identity, quality, or safety. FDA said the needles ... products are the pen label ...
Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. The Danish drugmaker ...
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback